Literature DB >> 33472635

TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3.

Shihai Liu1, Jing Qiu2, Guifang He1, Weitai He3, Changchang Liu1, Duo Cai1, Huazheng Pan4.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce substantial cytotoxicity in tumor cells but rarely exert cytotoxic activity on non-transformed cells. In the present study, we therefore evaluated interactions between TRAIL and IER3 via co-immunoprecipitation and immunofluorescence analyses, leading us to determine that these two proteins were able to drive the apoptotic death of hepatocellular carcinoma (HCC) cells and to disrupt their proliferative and migratory abilities both in vitro and in vivo. From a mechanistic perspective, we determined that TRAIL and IER3 were capable of inhibiting Wnt/β-catenin signaling. Together, these results indicate that TRAIL can control the pathogenesis of HCC at least in part via interacting with IER3 to inhibit Wnt/β-catenin signaling, thus indicating that this TRAIL/IER3/β-catenin axis may be a viable therapeutic target in HCC patients.

Entities:  

Keywords:  Hepatocellular carcinoma; Tumor necrosis factor-related apoptosis-inducing ligand; Wnt pathway

Year:  2021        PMID: 33472635      PMCID: PMC7816514          DOI: 10.1186/s12935-020-01724-8

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  56 in total

Review 1.  Death receptor agonist therapies for cancer, which is the right TRAIL?

Authors:  Pamela M Holland
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

Review 2.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Jessica Zucman-Rossi; Eli Pikarsky; Bruno Sangro; Myron Schwartz; Morris Sherman; Gregory Gores
Journal:  Nat Rev Dis Primers       Date:  2016-04-14       Impact factor: 52.329

Review 3.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.

Authors:  Christina Falschlehner; Tom M Ganten; Ronald Koschny; Uta Schaefer; Henning Walczak
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

4.  A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.

Authors:  Hyemin Kim; Dooyong Jeong; Hee Eun Kang; Kang Choon Lee; Kun Na
Journal:  J Pharm Pharmacol       Date:  2012-07-19       Impact factor: 3.765

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 6.  The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.

Authors:  Miryam Müller; Thomas G Bird; Jean-Charles Nault
Journal:  J Hepatol       Date:  2020-02-08       Impact factor: 25.083

7.  Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.

Authors:  L Zamai; M Ahmad; I M Bennett; L Azzoni; E S Alnemri; B Perussia
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

Review 8.  Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Authors:  Mohammed I Y Elmallah; Olivier Micheau
Journal:  Mar Drugs       Date:  2015-11-13       Impact factor: 5.118

9.  N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Authors:  Florent Dufour; Thibault Rattier; Sarah Shirley; Gaelle Picarda; Andrei Alexandru Constantinescu; Aymeric Morlé; Al Batoul Zakaria; Guillaume Marcion; Sebastien Causse; Eva Szegezdi; Dirk Michael Zajonc; Renaud Seigneuric; Gilles Guichard; Tijani Gharbi; Fabien Picaud; Guillaume Herlem; Carmen Garrido; Pascal Schneider; Chris Alan Benedict; Olivier Micheau
Journal:  Cell Death Differ       Date:  2017-02-10       Impact factor: 15.828

10.  Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.

Authors:  H Jin; K Lee; Y-H Kim; H K Oh; Y-I Maeng; T-H Kim; D-S Suh; J Bae
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

View more
  4 in total

1.  SIGNET: single-cell RNA-seq-based gene regulatory network prediction using multiple-layer perceptron bagging.

Authors:  Qinhuan Luo; Yongzhen Yu; Xun Lan
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

2.  Construction and validation of a novel apoptosis-associated prognostic signature related to osteosarcoma metastasis and immune infiltration.

Authors:  Yucheng Fu; Zhijian Jin; Yuhui Shen; Zhusheng Zhang; Meng Li; Zhuochao Liu; Guoyu He; Jintao Wu; Junxiang Wen; Qiyuan Bao; Jun Wang; Weibin Zhang
Journal:  Transl Oncol       Date:  2022-05-19       Impact factor: 4.803

3.  Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways.

Authors:  Fei-Yan He; Gang Chen; Rong-Quan He; Zhi-Guang Huang; Jian-Di Li; Wei-Zi Wu; Ji-Tian Chen; Yu-Lu Tang; Dong-Ming Li; Shang-Ling Pan; Zhen-Bo Feng; Yi-Wu Dang
Journal:  PeerJ       Date:  2022-03-10       Impact factor: 2.984

Review 4.  Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.

Authors:  Robby Barnestein; Loïck Galland; Laura Kalfeist; François Ghiringhelli; Sylvain Ladoire; Emeric Limagne
Journal:  Oncoimmunology       Date:  2022-09-13       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.